The 18 most recent market catalysts affecting $LEGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 85
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Legend Biotech reported highly positive five-year follow-up data for CARVYKTI in multiple myeloma, with 50% of patients remaining progression-free and an overall survival rate of 6…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 75
Legend Biotech Appoints Ingrid Zhang As CEO; Succeeds Alan Bash.
A CEO change, especially in a biotechnology company, can be a significant catalyst. Ingrid Zhang's appointment could signal a new strategic direction for Legend Biotech, potentiall…
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Legend Biotech, signaling continued confidence in the company's long-term prospects. However, the price target wa…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting
Legend Biotech is announcing that updated long-term follow-up data for its CARVYKTI drug from the CARTITUDE-2 trial will be presented at the IMS Annual Meeting in September 2026. T…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
Legence shares are trading lower after the company reported mixed Q2 financial results.
This headline signifies a direct corporate catalyst impacting Legence. Mixed financial results often lead to investor uncertainty, especially if the 'misses' outweigh the 'beats' o…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49
Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Legend Biotech (LEGN) and slightly raised the price target from $48 to $49. This action signals con…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 75
Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40
Oppenheimer analyst Trevor Allred downgraded Legend Biotech (LEGN) from Outperform to Perform and slashed the price target from $75 to $40. This significant revision by a major inv…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58
RBC Capital's analyst Leonid Timashev maintained an 'Outperform' rating for Legend Biotech, signaling continued confidence in the company's long-term prospects. However, the price …
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Legend Biotech, signaling a continued positive outlook on the company's fundamentals. However, the price target w…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Legend Biotech shares are trading higher after the company reported better-than-expected Q2 financial results.
The headline indicates a direct positive catalyst for Legend Biotech (LEGN) due to its strong financial performance. Better-than-expected results often lead to increased investor c…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 92
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
Legend Biotech reported Q2 adjusted EPS of $0.16, significantly surpassing the $0.07 consensus estimate, and sales of $387.5 million, beating the $355.772 million estimate. This st…
Aug 4, 2026
Market Technicals
Neutral
Impact 55
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The filing identifies Legend Biotech (LEGN), PTC Therapeutics (PTCT), and Indivior Pharmaceuticals (INDV) as 'oversold' based on their RSI values being below 30. This technical ind…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a 'Buy' rating and maintained a $65 price target for Legend Biotech (LEGN). This action signifies that the analyst's view …
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 75
Legend Biotech shares are trading lower after the company announced the resignation of its CEO Ying Huang. RBC Capital lowered its price target on the stock from $63 to $59.
The resignation of a CEO, especially in a biotechnology company where leadership often drives strategic direction and investor confidence, is a significant corporate catalyst. This…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $59
RBC Capital's decision to lower Legend Biotech's price target from $63 to $59, while maintaining an 'Outperform' rating, signals a nuanced view. This adjustment suggests that while…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 65
UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28
UBS analyst Ashwani Verma downgraded Legend Biotech from a 'Buy' to a 'Neutral' rating and cut the price target from $49 to $28. This significant reduction in price target, nearly …
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 55
JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target
JP Morgan's reinstatement of a 'Neutral' rating on Legend Biotech, accompanied by a $35 price target, provides an updated institutional perspective on the company. This matters bec…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.